SPRC News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

SP

Mkt Cap

$990,559

Volume

369.13K

Loading chart

SP

SPRCSciSparc Ltd. Ordinary Shares

SPRC

Pay with—

Available Balance0.00

SP

Mkt Cap

$1.2M

Volume

369.13K

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

Why Is SciSparc Stock Skyrocketing On Thursday?SciSparc Ltd. (NASDAQ: SPRC) stock surged 157% on Thursday following a pre-market announcement that its majority-owned subsidiary NeuroThera Labs Inc. received conditional regulatory approval from the TSX Venture Exchange. The approval clears the path for NeuroThera to acquire a 54% majority stake in CliniQuantum Ltd., an Israeli technology company that develops quantum simulation platforms for clinical trial data analysis. The deal, valued at approximately $9.459 million, aims to improve precision in clinical trial outcomes by identifying patient subpopulations responsive to investigational therapies.Benzinga · May 28, 2026

SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trailsSciSparc's majority-owned subsidiary NeuroThera Labs has signed a definitive agreement to acquire approximately 54% of CliniQuantum, a quantum technology company specializing in quantum-based clinical trials. NeuroThera will issue 56.6 million common shares valued at approximately $9.46 million, with potential earn-out payments up to $2.5 million based on patent filings and fundraising milestones. The transaction is expected to close by March 31, 2026.Benzinga · Mar 10, 2026

SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis CompanySciSparc's subsidiary NeuroThera Labs has signed a non-binding term sheet to acquire a 55% stake in an Israeli quantum computing bio data analysis company, aiming to leverage quantum computing principles for more efficient clinical data processing and research.Benzinga · Dec 2, 2025

SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical PortfolioSciSparc Ltd. has entered into an agreement to acquire a controlling interest in Miza III Ventures Inc., transferring its advanced clinical stage pharmaceutical portfolio and equity stake in SciSparc Nutraceuticals Inc. The transaction values the target assets at approximately $11.6 million and is expected to close around October 22, 2025.Benzinga · Oct 15, 2025

12 Health Care Stocks Moving In Monday's After-Market SessionMultiple health care stocks experienced significant price movements during Monday's after-market trading session, with some companies seeing notable gains while others experienced declines.Benzinga · Sep 29, 2025

SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung CancerSciSparc's majority-owned subsidiary MitoCareX, a drug discovery company targeting resistant cancers, was approved for acquisition by N2OFF. The transaction involves exchanging MitoCareX shares for N2OFF stock and includes financial support commitments.Benzinga · Sep 29, 2025

SciSparc Stock Shoots Up Over 89% After Hours: What's Going On?SciSparc's stock surged 89.13% after hours following a court-granted stay in its merger proceedings with AutoMax Motors until September 30, amid ongoing challenges in completing the merger agreement.Benzinga · Sep 17, 2025

SciSparc: AutoMax's Shareholders Approve Merger with SciSparcSciSparc Ltd. announced that shareholders of AutoMax Motors have approved a strategic merger, which will result in SciSparc acquiring 100% of AutoMax's share capital through a reverse merger, expanding into the automotive sector.Benzinga · Aug 28, 2025

Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightOver 50 companies are advancing cannabinoid drug research, exploring potential treatments for mental health disorders, neurodegenerative diseases, and chronic inflammation, with promising clinical trials targeting conditions like Alzheimer's, pain management, and epilepsy.GlobeNewswire Inc. · Aug 12, 2025

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SECSciSparc Ltd. announced progress on its proposed merger with AutoMax Motors Ltd., with the SEC declaring its Form F-4 registration statement effective. The merger involves SciSparc acquiring 100% of AutoMax's share capital through a reverse merger, with shareholder meetings scheduled in August 2025.Benzinga · Jul 30, 2025

to start trading

SP

SPRCSciSparc Ltd. Ordinary Shares

SPRC

Pay with—

Available Balance0.00

Your PositionYou don't own any SPRC yet.

Related Tickers

Earnings